Belzutifan(Welireg) is a novel therapeutic drug for tumors associated with von Hippel-Lindau (VHL) syndrome. It inhibits the growth of tumor cells by targeting HIF-2α and is indicated for specific types of renal cell carcinoma, central nervous system hemangioblastoma, and pancreatic neuroendocrine tumors.

The role and efficacy of Belzutifan

Belzutifan is a highly potent anti-cancer drug that exerts its antitumor effect by specifically inhibiting HIF-2α.

Mechanism of action

The main ingredient of Welireg is Belzutifan, which is able to effectively inhibit the function of HIF-2α, a protein that becomes overactive and promotes tumor growth under hypoxic conditions. By inhibiting HIF-2α, Belzutifan is able to slow the rate of tumor progression, providing patients with a new treatment option.

Scope of indications

Belzutifan is indicated for adult patients with VHL syndrome who require treatment for renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastoma, or pancreatic neuroendocrine tumor (pNET). These patients usually do not require immediate surgical treatment.

For patients who are unable to undergo surgery or who wish to seek a non-invasive treatment option, Belzutifan offers new hope.

How to buy Belzutifan?

Knowing how to obtain Belzutifan is important for patients who need this medication.

Domestic purchases

At present, Belzutifan has not been marketed in China, so patients cannot purchase this drug through domestic formal channels for the time being. However, with the deepening of the understanding of the disease and the growth of demand, it is possible for Belzutifan to enter the domestic market in the future.

For patients who urgently need medication, they can consider obtaining medication from legal sources abroad, but they need to pay attention to comply with relevant laws and regulations.

International Purchasing Channels

In countries such as the United States, Belzutifan has been approved and is available for purchase. The generic version produced by Lucius costs about $888 (40mg*90 tablets/box). Patients can legally purchase the medications they need from these areas.

Finding reliable international purchasing channels can help patients get the necessary treatment in a timely manner.

How to use Belzutifan?

Proper use of Belzutifan is key to confirming efficacy and reducing side effects.

Recommended dosage and administration

The recommended dose of Belzutifan is 120 mg orally once daily until disease progression or unacceptable toxicity. It is recommended that patients should take it at the same time every day and can take it with or without meals. If you miss a dose of medication, you can make up the dose as soon as possible on the same day; If you vomit after taking it, you don't need to take it again and continue to take the medicine as usual the next day.

Precautions

Concomitant use of UGT2B17 or CYP2C19 inhibitors should be avoided during the use of Belzutifan, and concomitant use with sensitive CYP3A4 substrates and hormonal contraceptives is not recommended. In addition, pregnant women, lactating women, and men and women of childbearing potential should take effective contraceptive measures when using this product.

Knowing and following the correct medication guidance not only improves treatment outcomes but also minimizes unnecessary health risks.